Volume 14, Issue 1 (volume 14, number 1 2022)                   IJDO 2022, 14(1): 9-13 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Adhe Rojekar A, Vijay Rojekar M, B. Ghanghurde S, Lalla P. HbA1c in Polycystic Ovary Syndrome as the Cardiac Risk Assessment. IJDO. 2022; 14 (1) :9-13
URL: http://ijdo.ssu.ac.ir/article-1-681-en.html
Family Physician, Chembur, Mumbai, India.
Abstract:   (797 Views)
Objective: Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with hyperandrogenism marked with hirsutism and ovarian dysfunction. These conditions may lead to the risk of insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease. These conditions are related to PCOS complications hence our aim was to study and investigate the relationship between high-sensitivity C - reactive protein (hs-CPR) level and glycosylated hemoglobin (HbA1c) level in PCOS patients.
Materials and Methods: Female patients visiting the obstetrics and gynecology outpatient department (OPD), aged between 19 and 45 years with a body mass index (BMI) of 25 to 29 kg/m2. The individuals fulfilling the National Institute of Health (NIH) criteria for PCOS; including amenorrhea or oligomenorrhea and had been clinically diagnosed with hyperandrogenism were served as subjects.
Results: Two hundred and ten individuals with HbA1c of 5.4% have a higher risk of cardiovascular disorders. The study showed the association between increased cardiac risk as measured by hs-CRP and patients with normal HbA1c values with a sensitivity of 77.2% and specificity of 75.99%. The HbA1c cutoff value can be used in the PCOS patients to assess the cardiac risk due to association of HbA1c cut off value with false positivity rate of 15.24%.
Conclusion: In PCOS patients with chronic low-grade inflammation, IR, and the degree of inflammation associated with HbA1c value was observed.
Full-Text [PDF 475 kb]   (154 Downloads)    
Type of Study: Research | Subject: Special
Received: 2021/09/25 | Accepted: 2022/01/1 | Published: 2022/02/26

References
1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018;14(5):270-84. [DOI:10.1038/nrendo.2018.24]
2. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia FJ. Genetic, hormonal and metabolic aspects of PCOS: an update. Reproductive Biology and Endocrinology. 2016;14(1):1-7. [DOI:10.1186/s12958-016-0173-x]
3. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. The Journal of steroid biochemistry and molecular biology. 2018;182:27-36. [DOI:10.1016/j.jsbmb.2018.04.008]
4. Mortada R, Kallail KJ, Dong F, Karakas S. HbA1c in patients with polycystic ovary syndrome: a potential marker of inflammation. Journal of reproduction & infertility. 2015;16(4):203-206.
5. Ün B, Dolapçıoğlu KS, Okyay AG, Şahin H, Beyazıt A. Evaluation of hs-CRP and visseral adiposity index in patients with policystic ovary syndrome by clinical and laboratory findings. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016 ;204:16-20. [DOI:10.1016/j.ejogrb.2016.06.022]
6. Rezaee M, Asadi N, Pouralborz Y, Ghodrat M, Habibi S. A review on glycosylated hemoglobin in polycystic ovary syndrome. Journal of pediatric and adolescent gynecology. 2016;29(6):562-6. [DOI:10.1016/j.jpag.2016.07.001]
7. Mohammad MB, Seghinsara AM. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):17.
8. Witchel SF, Burghard AC, Tao RH, Oberfield SE. The diagnosis and treatment of PCOS in adolescents: an update. Current Opinion in Pediatrics. 2019;31(4):562-9. [DOI:10.1097/MOP.0000000000000778]
9. Mayer SB, Evans WS, Nestler JE. Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Women's Health. 2015;11(2):137-49. [DOI:10.2217/WHE.14.73]
10. Odsæter IH, Åsberg A, Vanky E, Carlsen SM. HbA1c as screening for gestational diabetes mellitus in women with polycystic ovary syndrome. BMC endocrine disorders. 2015;15(1):1-9. [DOI:10.1186/s12902-015-0039-9]
11. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103(9):1194-7. [DOI:10.1161/01.CIR.103.9.1194]
12. Wander K, Brindle E, O'Connor KA. C‐reactive protein across the menstrual cycle. American Journal of Physical Anthropology: The Official Publication of the American Association of Physical Anthropologists. 2008;136(2):138-46. [DOI:10.1002/ajpa.20785]
13. Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, et al. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology. 2014;30(11):781-4. [DOI:10.3109/09513590.2014.924099]
14. Sumithra NU, Lakshmi RL, Leela Menon N, Subhakumari KN, Sheejamol VS. Evaluation of oxidative stress and hsCRP in polycystic ovarian syndrome in a tertiary care hospital. Indian journal of clinical biochemistry. 2015;30(2):161-6. [DOI:10.1007/s12291-014-0427-3]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb